Search

News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?

In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?

Source: Chronic Kidney Disease 8. 6. 2021

News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment

The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.

Source: Oncological Treatment 15. 10. 2021

News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis

What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC). .

Source: Amyloidosis 27. 2. 2023

News The Immune System in the Pathophysiology of ITP

From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.

Source: Immune Thrombocytopenia 9. 4. 2022

News How to Prevent and Treat Thromboembolic Disease in Cancer Patients

Malignancy is one of the risk factors for the development of thromboembolic disease (TED). Venous thromboembolism is considered the second most common cause of death in cancer patients, with the top cause being the cancer itself. Therefore, optimal treatment and timely prevention of these complications is very important.

Source: Thromboprophylaxis 6. 3. 2021

News After 20 years, a new treatment option for primary biliary cholangitis arrives

Primary biliary cholangitis (PBC), formerly known as cirrhosis, is a rare disease with a negative impact on prognosis and quality of life. While ursodeoxycholic acid (UDCA) has been essentially the only treatment option for PBC so far, in 2016, the European Medicines Agency (EMA) approved obeticholic acid as a second-line option. Since 2019, this medication has been available and fully covered by health insurance in 11 selected centers in the Czech Republic.

Source: Primary Biliary Cholangitis 10. 6. 2020

News Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?

Diabetic autonomic neuropathy can affect various organ systems. Cardiovascular autonomic neuropathy is one of its most severe forms with a significant impact on patient morbidity and mortality. How can it be detected in clinical practice?

Source: Diabetes 27. 1. 2022

News Expanded Vaccination Option Against Pneumococci Thanks to 15valent Vaccine

Our arsenal for preventing pneumococcal diseases has been expanded with a 15-valent conjugate vaccine that includes important serotypes causing invasive pneumococcal diseases (IPD). The following text briefly summarizes basic information not only about IPD, their prevention, diagnosis, and treatment, but especially about the management of vaccination with the 15-valent vaccine in practice.

Source: Regular Vaccination 20. 6. 2023

News Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?

How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.

Source: Hematologic Malignancies 27. 4. 2022

News How do patients perceive the treatment of ITP with romiplostim?

Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.

Source: Immune Thrombocytopenia 15. 4. 2024

News Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab

The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 3. 2024

News Alzheimer's Disease: Diagnosis Step by Step in 4 Points

Alzheimer's disease is the most common cause of dementia. With the aging population, this topic is becoming increasingly relevant. How have the knowledge and diagnostic possibilities of the disease progressed over the past decades?

Source: Cognitive in the treatment of Alzheimer's disease 16. 6. 2020

News Insufficiently Controlled Epilepsy Reduces Quality and Length of Life

The effects of uncontrolled epilepsy far exceed the moment of a seizure, having a substantial impact on the psychological and physical well-being of patients. These individuals often sustain injuries during seizures, leading to reduced mobility, a higher risk of associated diseases, and premature death.

Source: Epilepsy 7. 4. 2022

News Noonan Syndrome (Not Just) in the Pediatric Cardiologist's Office

Noonan Syndrome (NS) is a genetically determined disease associated with a high prevalence of (not just) congenital heart defects. When is it necessary to consider it in a cardiologist's office, where to refer the patient if suspected, and how to proceed if the diagnosis is confirmed?

Source: Growth Disorders 23. 2. 2021

Články časopisu Global Allergy and Asthma European Network (GA²LEN) addresses the epidemic of allergy and asthma

Author of the article: Petr Panzner, Petr Čáp, Peter Burney, Torsten Zuberbier, Paul Van Cauvenberg, Jean Bousquet Source: Časopis lékařů českých | 1/2010 1. 1. 2010